Emergent Biosolutions
EBS
295 hedge funds and large institutions have $2.57B invested in Emergent Biosolutions in 2018 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 108 increasing their positions, 104 reducing their positions, and 31 closing their positions.
179% more call options, than puts
Call options by funds: $3.06M | Put options by funds: $1.1M
32% more capital inflows, than outflows
Capital inflows: $302M | Capital outflows: $229M
13% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 31
7% more funds holding
Funds holding: 275 → 295 (+20)
4% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 104
0.16% more ownership
Funds ownership: 84.82% → 84.98% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$62.5M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$20.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$19.7M |
| 4 |
Atlanta Capital Management
Atlanta,
Georgia
|
+$16.9M |
| 5 |
Friess Associates
Greenville,
Delaware
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$21.6M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$20M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19.6M |
| 4 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$18.1M |
| 5 |
Renaissance Technologies
New York
|
-$17.7M |
EBS Hedge Fund Activity: Q4 2018 in Review
295 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2018, worth a combined $2.57B — down 8.1% from $2.79B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new EBS positions and 31 closed out — a net gain of 4 holders — while 108 added to existing stakes and 104 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $62.5M. The largest seller was Acadian Asset Management, cutting an estimated $21.6M.
- 295 institutional investors held Emergent Biosolutions (EBS) as of Q4 2018, up from 275 in Q3 2018.
- Funds reported $2.57B of Emergent Biosolutions stock for Q4 2018, down 8.1% quarter-over-quarter.
- 35 funds opened new Emergent Biosolutions positions in Q4 2018 and 31 closed out, a net change of +4 holders.
- The largest Emergent Biosolutions buyer in Q4 2018 was Neuberger Berman Group, an estimated $62.5M added.
- The largest Emergent Biosolutions seller in Q4 2018 was Acadian Asset Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q4 2018.